RYBELSUS 7/MG TAB 30/TAB

Indications

Approved Uses

As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Dosage & Administration

Dosing by Condition

Type 2 diabetes mellitus (adults): 3 mg PO once daily for 30 days, then 7 mg PO once daily; if additional glycemic control is needed after at least 30 days on 7 mg, increase to 14 mg PO once daily (max 14 mg daily).

Initial Dose

3 mg once daily for the first 30 days

Maintenance Dose

7 mg once daily; may increase to 14 mg once daily if additional glycemic control is needed

Maximum Dose

14 mg once daily.

Dose Adjustment Notes

Initiate 3 mg once daily for 30 days (for initiation only; not effective for glycemic control), then increase to 7 mg once daily; if needed, increase to 14 mg once daily after at least 30 days on 7 mg. Consider reducing concomitant insulin or sulfonylurea dose to lower hypoglycemia risk; no routine dose adjustment is required for renal or hepatic impairment, but monitor renal function if severe GI reactions occur.

How to Take

Take Rybelsus once daily on an empty stomach upon waking, at least 30 minutes before the first food, beverage, or other oral medications of the day. Swallow the tablet whole (do not split, crush, or chew) with no more than 120 mL (4 ounces) of plain water only.

Side Effects

Common Side Effects

Nausea, diarrhea, abdominal pain, decreased appetite, vomiting, constipation (common); dyspepsia/indigestion and reflux/eructation can also occur.

Safety & Warnings

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); known serious hypersensitivity to semaglutide or any excipients.

Warnings & Precautions

Risk of thyroid C-cell tumors (boxed warning; contraindicated with personal/family history of MTC or MEN2); pancreatitis (discontinue if suspected; do not restart if confirmed); diabetic retinopathy complications; hypoglycemia with concomitant insulin/secretagogues; acute kidney injury (especially with severe GI reactions/dehydration); acute gallbladder disease; serious hypersensitivity reactions; delayed gastric emptying may affect absorption of concomitant oral medications.

Drug Interactions

Drug Interactions

Insulin and insulin secretagogues (e.g., sulfonylureas): increased hypoglycemia risk (may require dose reduction); oral drugs: semaglutide delays gastric emptying and can affect absorption-use caution/monitor with narrow therapeutic index drugs; levothyroxine: increased exposure-monitor as clinically indicated.

Interaction Severity

MAJOR: Insulin and sulfonylureas/secretagogues (increased hypoglycemia risk-consider dose reduction and monitor). MODERATE: Levothyroxine (increased exposure reported-monitor thyroid parameters/clinical response); other oral drugs may have altered absorption due to delayed gastric emptying-use caution with narrow therapeutic index drugs and monitor as appropriate. Warfarin: monitor INR when clinically indicated.

Food Interaction

Food and beverages markedly reduce absorption: take on an empty stomach with no more than 120 mL (4 ounces) of plain water only, and wait at least 30 minutes before eating, drinking, or taking other oral medications.

Special Populations

Pregnancy

Insufficient data available; animal studies showed early pregnancy losses and fetal abnormalities at clinically relevant doses; use only if benefits justify potential risks

Elderly

Standard adult dosing; no dose adjustment required based on age alone, but monitor renal function and hydration status due to increased risk of dehydration from GI side effects

Kidney Impairment

No dose adjustment required for mild to severe renal impairment; use caution in end-stage renal disease and monitor renal function if severe GI reactions occur (risk of dehydration/AKI).

Liver Impairment

No dose adjustment required in hepatic impairment.

Storage & Patient Advice

Missed Dose

If a dose is missed, skip it and take the next dose the following day at the usual time; do not take two doses in the same day.

Patient Counseling

Take Rybelsus (oral semaglutide) once daily in the morning on an empty stomach, at least 30 minutes before the first food, beverage, or other oral medicines. Swallow the tablet whole with no more than 120 mL (about 4 oz) of plain water only; do not split, crush, or chew. If you miss a dose, skip it and take the next dose the following day. Common GI effects (nausea/diarrhea/vomiting) are dose-related and often improve; eat smaller, lower-fat meals and maintain hydration. Seek urgent care for severe/persistent abdominal pain (possible pancreatitis) or symptoms of gallbladder disease; monitor for hypoglycemia if used with insulin or a sulfonylurea. Report possible thyroid tumor symptoms (neck lump, dysphagia, hoarseness) and avoid use in patients with personal/family history of medullary thyroid carcinoma or MEN2; avoid in pregnancy/planning pregnancy per labeling.

Monitoring Requirements

Monitor glycemic control (HbA1c and/or SMBG as clinically appropriate); monitor for pancreatitis symptoms; monitor renal function if severe GI reactions/dehydration occur; monitor for diabetic retinopathy worsening in patients with pre-existing retinopathy; counsel/monitor for thyroid C-cell tumor risk symptoms per class boxed warning.

Pharmacology

Mechanism of Action

GLP-1 receptor agonist: increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, slows gastric emptying (especially early in therapy), and reduces appetite/energy intake.

Half-Life

Approximately 1 week (168 hours)

Bioavailability

Approximately 0.4-1% absolute oral bioavailability (very low; enabled by SNAC co-formulation).

Metabolism

Proteolytic cleavage of the peptide backbone with sequential beta-oxidation of the fatty-acid side chain; not significantly metabolized by CYP450 enzymes.

Excretion

Eliminated as metabolites via both urine and feces (approximately split between renal and fecal routes; no meaningful unchanged semaglutide excretion).

Product Information

Available Dosage Forms

Tablet (oral).

Composition per Dose

Each tablet: 7 mg semaglutide (as base) with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate) absorption enhancer

Generic Availability

No

OTC Alternatives

No OTC alternative

Diabetes Type

Type 2

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

• Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
• Any discrepancy between the information provided and the product's package insert or SFDA guidelines
• Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.